IKS Health

Q1 FY 27 Investor Presentation

Disclaimer

This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the statements themselves. Such statements comprise the company's current visibility on market movements, client discussions, and related factors. Inventurus Knowledge Solutions Limited does not assume an obligation to update or revise any forward-looking statements.

IKS Health - a comprehensive healthcare enablement platform empowering provider organizations

Total Addressable Market[1,2]

US$5tn
US Healthcare Expenditure (CY2024)

US$260bn / US$34bn
TAM / Outsourced Market (CY2023)

8% / 12%
TAM / Outsourced Market CAGR (2023-2028E)

Established Client Relationships

600+/650+
Healthcare Organizations Q1 27/Q1 26

85%+
Revenues from Repeat Customers

5+ Years
Top 10 / Top 5 Clients Average Vintage (As of Mar 31, 2026)

Specialised workforce

12,889 / 1,902
Employees / Clinically trained staff (As of June 30, 2026)

565
Technology Focused Employees (As of June 30, 2026)

57
Sales & Marketing Employees (As of June 30, 2026)

The only Comprehensive platform that delegates all chores across the patient journey

Adding a technology-enabled layer to 'care delivery pyramid' to help Physician Enterprises achieve optimized revenue and reduced expenses

IKS HEALTH

Note: Numbers Rounded off to nearest Integer / percent; 1. Source: Zinnov Report; 2. TAM- Total Addressable Market for RCM, VBC, Patient, Coding and Client Services. 3. Repeat clients refers to clients who availed our platform or solutions during the previous period, and revenue generated from such clients are calculated for the relevant period

IKS Health: 5 strategic pillars of execution

IKS HEALTH

Integrated System of Action (SOA) & System of Record (SOR) for rural/ community health system market

- Create the **structured unified data** moat for **AI training** (5MM+ longitudinal records) that enable our SLM's
- **Train our proprietary SLM's that power** the **interconnected workflows leveraging the above AI Training moat**
- Build **explainability** in each of the Generative AI driven workflows; and empower with **human-in-the-loop** (HITL) and/or **Rules-based AI** for deterministic outcomes
- **Embed** the SOA agentic workflows in the native **SOR** (Electronic Health Record - EHR) **workflows**

Proprietary models driven comprehensive System of Action with API integration for large medical group market

- **Translate** the trained agentic workflows from Rural/ Community settings to the large group and ambulatory settings and vice versa
- Build **API-powered integration** with relevant **EHRs**
- Embody **Explainability** for Generative AI and **HITL** where applicable
- Continue to pursue **feature-based KLAS leadership** while demonstrating **interconnected end to end agentic workflows** (platform capabilities)

Drive growth momentum through re-stratified key growth levers

- Pick up **land and expand** (cross sell) momentum in installed base of **Large Health Systems**
- **Cross sell System of Action** (SOA) in the **Rural/ Community** (TruBridge) installed base
- **Platform** sales in **mid-size Health Systems / Medical Groups**

Get back to optimized margins through operating model transformation and synergies

- Evolve from Tech led, HITL to **Autonomy through explainable AI** for non-deterministic outcomes
- Execute **Operating model Transformation** in TruBridge RCM & Coding Businesses
- Realize **Operating** and **SG&A Synergies**

Culture and leadership

- Continue to institutionalize an **outcome driven culture** and **operating model** to enable **outcome based deals**
- **Consolidated Leadership team** leveraging **complementary** strengths and capabilities
- **One Unified Culture** based on intentional manifest of **value behaviors**

Awards and Recognition

US Patent US 12,619,923 B2 for Engagement Learning Engine

AI-driven "Awareness-Ability-Willingness" (AAW) behavioral modeling powers IKS Health's patient access solutions including MyCareHub which enhance patient engagement and optimize patient scheduling.

2026 Dallas-Fort Worth Titan 100

Titan CEO - Sachin K. Gupta, Founder & Global CEO

Best CFO & Finance Strategy Excellence Awards 2026

1. Excellence in Investor Relations (Organisational category)
2. Best CFO in Healthcare – Nithya Balasubramanian, Whole-time Director & Group CFO (Individual category)

Awards and Recognition

FINANCIAL EXPRESS.com
HR AWARDS 2026

FE HR Awards 2026

Excellence in Onboarding & Role Enablement

AMGA™

American Medical Group Association (AMGA)


Distinguished Corporate Partner Award 2026




Axia Women's Health

IKS Health partnership for medical coding delivered $12 Million in annual cash impact with 96%+ coding accuracy and 37% lower coding related denials

IKS Health enables care transformation *across the patient journey*





IKS HEALTH

Q1 - Strong growth while delivering *continuous margin expansion*

Growth At Scale

INR 8,936 mn
Revenue from Operations

21%
YoY growth in INR

12%
YoY growth in USD

Deep Client Relationships

450+
Enterprise level customers

INR mn 3,759
Revenue from Top 10 customers

5.76 / 7.41 years
Top 10 / Top 5 Clients Average Vintage

Strong Margin Profile

33%
EBITDA (in spite of one-time acquisition costs)

22%
PAT Margin

24%/28%
YoY growth in EBITDA/PAT

Globally Diversified Workforce

12,889
Total Employees


1,902 / 565
Clinical /tech focussed employees

43%
Women employees

IKS HEALTH

Q1 FY 27: Growing *faster than market* with *strong margins*


Revenue
INR Mn



20.7% YoY

4.2% QoQ


EBITDA
INR Mn



24.0% YoY (even higher if not for one-time acquisition costs)

1.8% QoQ (due to one-time acquisition costs and reduction in currency gains)


PAT
INR Mn



27.8% YoY

5.9% QoQ

Adjusted PAT*
INR Mn




28.0% YoY

5.1% QoQ

*Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition which is a non-cash expense.

Q1 FY 27 – Continued strong *cash generation* supporting growth aspirations


OCF & FCF
INR Mn



↑ 20.5% OCF YoY

↑ 26.9% FCF YoY

Net Debt
INR Mn



OCF and FCF are adjusted for upfront guarantee payment of economic value add made to a customer, for Rs 1,430 mn in Q1 FY 27.

Key deal wins

Premier California Health System

Strategic partnership with premier integrated health system in California for a comprehensive clinical data migration for an acquired hospital, seamlessly unifying legacy records into their enterprise EHR. Establishes a framework that positions IKS as a preferred partner for additional facility migrations across the growing group footprint.



National Musculoskeletal Leader

Reuniting with one of the leaders in musculoskeletal space. The collaboration focuses on modernizing end-to-end RCM functions. By optimizing back-office functions, the clinical provider can better focus on delivering highly customized, life-enhancing physical interventions to patients nationwide.

ADVOCATE HEALTH

One of country's top health systems Advocate Health, an existing client, is significantly expanding its partnership across RCM including coding in volume and value efforts across its entire network in the acute and ambulatory space.


StrideCare

Existing customer StrideCare is a large Texas multi-specialty physician group that acquired a vein, vascular, and podiatry specialty group and extended RCM services, indicating organic growth and practice expansion.

IKS HEALTH


Q1 FY 27 - *Improving EPS* and maintaining *high ROE*

EPS ₹



EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.

ROE %*



Return on Equity is calculated as profit for the period divided by average equity balance during the period.

*ROE declined due to increased equity base from revaluation of Abridge, alongside lower earnings from reduced currency gains and one-time acquisition costs.

Financials - Summary INR millions

INR Mn

Particulars	Q1 FY 27	Q1 FY 26	YoY%	Q4 FY 26	QoQ%
Revenue USD mn	97	87	12.0%	95	2.5%
Revenue	8,936	7,401	20.7%	8,577	4.2%
Forex Gain/ (Loss)	12	12	3.2%	352	-96.6%
Employee benefit expense excluding ESOP	4,332	3,871	11.9%	4,011	8.0%
Other Expenses*	1,449	1,075	34.8%	1,743	-16.9%
EBITDA excluding ESOP	3,167	2,467	28.4%	3,175	-0.2%
EBITDA excluding ESOP %	**35.4%**	**33.3%**	**2.1%**	**37.0%**	**-1.6%**
ESOP Cost	218	89	145.4%	173	26.2%
EBITDA	**2,949**	**2,378**	**24.0%**	**3,002**	**-1.8%**
EBITDA %	**33.0%**	**32.1%**	**0.9%**	**35.0%**	**-2.0%**
Finance cost	101	181	-44.1%	127	-20.2%
Depreciation and amortisation	343	279	22.9%	341	0.7%
Interest income	57	31	85.3%	49	17.2%
Profit before exceptional items and tax	**2,563**	**1,949**	**31.5%**	**2,584**	**-0.8%**
Profit before exceptional items and tax %	**28.7%**	**26.3%**	**2.3%**	**30.1%**	**-1.4%**
Tax expense	572	433	32.0%	470	21.7%
Profit for the period before Share of Associates	**1,990**	**1,515**	**31.4%**	**2,114**	**-5.8%**
Profit for the period before Share of Associates %	**22.3%**	**20.5%**	**1.8%**	**24.6%**	**-2.4%**
Share of Profit/(Loss) from Associates (net of tax)	(53)		0.0%	(54)	-1.9%
Profit for the period	**1,937**	**1,515**	**27.8%**	**2,060**	**-5.9%**
Profit for the period %	**21.7%**	**20.5%**	**1.2%**	**24.0%**	**-2.3%**
Amortisation of Intangible assets	216	167	29.2%	210	2.8%
Adjusted Profit for the period	**2,153**	**1,682**	**28.0%**	**2,269**	**-5.1%**
Adjusted Profit for the period %	**24.1%**	**22.7%**	**1.4%**	**26.5%**	**-2.4%**


IKS HEALTH

*Includes acquisition expenses incurred in current quarter and last quarter


Other KPI Metrics

Particulars	Q1 FY 27	Q1 FY 26	Q4 FY 26
Annualised Adjusted EBITDA per employee in INR mn	0.99	0.81	0.98
Revenue from Top 10 customers INR mn	4,808	3,213	4,525
Contribution from Top 10 customers	53.8%	43.4%	52.8%
Revenue from Top 5 customers INR mn	3,759	2,349	3,564
Contribution from Top 5 customers	42.1%	31.7%	41.5%
Ageing of Top 10 clients (number of years)	5.76	5.54	5.42
Ageing of Top 5 clients (number of years)	7.41	5.52	5.56
FCF Yield (%)	89.9%	84.5%	62.1%

A decade of *consistent profitable growth*



Medium-Term Financial Outlook



Strategic Outlook: Sustained EBITDA expansion without significant dilution of Equity.

IKS HEALTH

Thank You